Recent investigation has elucidated tumor cell-level mechanisms that account for suboptimal responses to HER2-targeted therapies, including overexpression of EGFR, cMYC, or ERBB3, and mutational loss of PTEN or activation of PI3K [21]. This evidence concerns the gene MYC and neoplasm.